Drugs / Live Attenuated Influenza Vaccine
Live Attenuated Influenza Vaccine
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05056519 | Sep → Dec 2021 | — | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT07133802 | Aug 2025 → Mar 2026 overdue | — | Changchun BCHT Biotechnology Co. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02964065 | Nov 2016 → Aug 2017 | influenza | Changchun BCHT Biotechnology Co. | Completed | Met primary |
| Phase 47 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07093281 | Feb → Apr 2026 overdue | — | University of Maryland, Baltimore | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06501963 | Oct 2024 → Apr 2025 | influenza | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02866942 | Oct 2016 → Mar 2017 | asthma | Imperial College London | Completed | Missed primary |
| Phase 4 | NCT02549365 | Oct 2015 → Apr 2016 | — | Imperial College London | Completed | Missed primary |
| Phase 4 | NCT02111512 | Sep 2014 → Feb 2015 | food allergy | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT01194297 | Aug 2010 → May 2012 | influenza | University of Rochester | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00138294 | Oct 1998 → Jun 2010 | influenza | Baylor College of Medicine | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT04110366 | Jun 2018 → Apr 2019 | influenza | Imperial College Healthcare NHS Trust | Completed | No outcome recorded |
| — | NCT01673425 | Sep → Dec 2012 | influenza | National Center for Occupational Health and Infection Control | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT01545349 Background | Feb 2012 → May 2013 | influenza | Patricia L. Hibberd | Completed | No outcome recorded |
| Phase 2 | NCT05284851 Comparator | Apr → May 2022 | — | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
| Phase 4 | NCT01653015 Comparator | Nov 2012 → Jun 2015 | influenza | McMaster University | Completed | Missed primary |
| Phase 4 | NCT03101462 Comparator | Feb → May 2011 | influenza | St. Louis University | Completed | No outcome recorded |
| Phase 4 | NCT01246999 Comparator | Oct 2010 → Jan 2013 | influenza | University of Rochester | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Attenuated Influenza Vaccine | “Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination...” NCT00138294 ↗16“Nasal Spray Live Attenuated Influenza Vaccine” NCT07133802 ↗ |
| Known as | CAIV-T | “trivalent live-attenuated influenza vaccine (CAIV-T)” PMID 17395338 ↗ Mar 2007 |
| Known as | Fluenz-Tetra | “Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune)” NCT04110366 ↗ |
| Known as | FluMist | “Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune)” NCT04110366 ↗ |
| Known as | LAIV | “A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years” NCT07133802 ↗5“Live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) are available for children.” PMID 25165161 ↗ Aug 2014 “A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine)” NCT02866942 ↗ “Administration of Live attenuated influenza vaccine (LAIV)” NCT02111512 ↗ “live attenuated influenza vaccine (LAIV or FluMist)” NCT00138294 ↗ “Live-Attenuated influenza Vaccine(LAIV)” NCT02964065 ↗ |
| Known as | LAVI | “Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non...” NCT05056519 ↗ |
| Known as | Live Attenuated Intranasal Vaccine | “A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine) has recently been approved” NCT02111512 ↗1“A new influenza vaccine, known as LAIV (Live Attenuated Intranasal Vaccine)” NCT02866942 ↗ |
| Modality | Vaccine | “live attenuated influenza vaccine” NCT00138294 ↗ |
| Route | Intranasal | “Each subject will receive by nasal spray a 0.2 ml dose (0.1 ml in each nostril) of the LAIV” NCT00138294 ↗ |